Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients (PHYOX4)
A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
A PHASE1 clinical study on Primary Hyperoxaluria Type 3, this trial is completed. The trial is conducted by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company and has accumulated 10 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Oct 2021 — Jun 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
-
May 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE1
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
For direct contact, visit the study record on ClinicalTrials.gov .